Translating Cardioprotection for Patient Benefit

Acute myocardial infarction and the subsequent development of heart failure are among the leading causes of death and disability globally. The most effective treatment for limiting infarct size and preventing subsequent heart failure is timely interventional or surgical reperfusion, but even then, mortality and morbidity remain significant (1). Accordingly, new treatments are required, but the translation of adjunct cardioprotection to clinical practice has been largely disappointing so far (2). Reasons for such poor translation and novel strategies are addressed in the ongoing European Union (EU)-CARDIOPROTECTION Cooperation in Science and Technology (COST) Action (CA16225).